<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071118</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R71/2021</org_study_id>
    <nct_id>NCT05071118</nct_id>
  </id_info>
  <brief_title>The Efficacy of Pregabalin on the Duration of the Spinal Anesthesia and the Early Postoperative Pain After Total Knee Arthroplasty</brief_title>
  <official_title>the Effect of Adding Pregabalin on the Onset and the Duration of Spinal Anesthesia and on the Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of this study is to evaluate the effectiveness of administration of pregabalin 2&#xD;
      hours preoperatively on the onset and the duration of the spinal anesthesia in total knee&#xD;
      arthroplasty and the role of pregabalin in postoperative analgesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Actual">August 25, 2021</completion_date>
  <primary_completion_date type="Actual">August 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>onset of spinal anaesthesia</measure>
    <time_frame>three months</time_frame>
    <description>seventy participants undergoing elective total knee arthroplasty under spinal anesthesia half of them took placebo and the other half took 150 mg pregabalin two hours before the procedure and calculate the time from the base line to the onset of anesthesia.&#xD;
Our primary outcome is to assess the onset of spinal anesthesia.&#xD;
to detect the onset of spinal anaesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>three months</time_frame>
    <description>Recovery time from the sensory blockade (2-dermatome regression of anesthesia from the maximum level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motor block duration</measure>
    <time_frame>three months</time_frame>
    <description>the time for return to Bromag 2 (the patient is able to move knees and ankles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative analgesia</measure>
    <time_frame>three months.</time_frame>
    <description>â€¢ Postoperative pain will be assessed by the patient using the visual analog scale in the first 24 hour(VAS, 0=no pain; 10=worst possible pain) every 2 hours up to 24 hours after the operation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>pregabalin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two hours before surgery, the pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery</description>
    <arm_group_label>pregabalin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the ages of 40 and 70 years&#xD;
&#xD;
          -  height 155-170 cm&#xD;
&#xD;
          -  American Society of Anesthesiologists grade I or II .&#xD;
&#xD;
          -  patients underwent total knee arthroplasty under spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients known to be allergic to any medicines.&#xD;
&#xD;
          -  patients had a history of drug or alcohol abuse.&#xD;
&#xD;
          -  patients were taking opioids or sedative medications,&#xD;
&#xD;
          -  patients Inability to communicate with investigators to evaluate the postoperative&#xD;
             pain&#xD;
&#xD;
          -  patients were in need for postoperative ICU hospitalization .&#xD;
&#xD;
          -  patients had a history of psychiatric conditions.&#xD;
&#xD;
          -  Patients with a history of taking pregabalin or gabapentin .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ismail Mohammed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

